Revisiting Freund's incomplete adjuvant for vaccines in the developing world

Area of Science:

• Immunology
• Vaccinology
• Global Health

Background:

• Public-private partnerships are crucial for addressing global health challenges, particularly in developing nations.
• Industry reluctance to develop high-impact but low-profit health products, like Freund's incomplete adjuvant (FIA), stems from litigation risks associated with adverse reactions.
• FIA presents a case for public sector development due to its potential in treating diseases prevalent in developing countries.

Purpose of the Study:

• To present evidence supporting the use of Freund's incomplete adjuvant (FIA) in vaccine development.
• To highlight FIA's potential benefits for vaccines targeting blood-stage malaria.
• To propose a path forward for creating safe, effective, and affordable vaccines for malaria and other critical diseases in developing regions.

Main Methods:

• Review of existing evidence on Freund's incomplete adjuvant (FIA).
• Analysis of FIA's potential efficacy in preclinical models for malaria.
• Exploration of strategies for public sector-led vaccine development.

Main Results:

• Evidence suggests Freund's incomplete adjuvant (FIA) has significant potential as a component in malaria vaccines.
• The risk-benefit profile of FIA makes it less attractive for private industry investment.
• Public sector involvement is indicated as a viable route for FIA development.

Conclusions:

• Freund's incomplete adjuvant (FIA) warrants further investigation and development, preferably within the public sector.
• Developing safe and effective vaccines for diseases affecting the developing world requires innovative approaches to product development.
• Collaboration and strategic investment are key to overcoming barriers in creating accessible health solutions for global diseases.